Classification and pharmacology of progestins

Hulley, 1998, Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women, heart/estrogen-replacement-study (HERS I) group, JAMA, 280, 605, 10.1001/jama.280.7.605 Grady, 2002, Cardiovascular disease outcomes during 6.8 years of hormone replacement therapy. Heart estrogen/progestin replacement study follow-up (HERS II), JAMA, 288, 49, 10.1001/jama.288.1.49 Hulley, 2002, Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart estrogen/progestin replacement study follow-up (HERS II), JAMA, 288, 58, 10.1001/jama.288.1.58 Writing Group for the Women’s Health Initiative Investigators Risks and Benefits of Estrogen plus Progestin in Healthy Postmenopausal Women. JAMA 2002;288:321–33. Million women collaborators. Breast cancer and hormone-replacement therapy in the million-women-study. Lancet 2003;362:419–27. Schindler, 1996, Progestins: present and future, J. Steroid Biochem. Molec. Biol., 59, 357, 10.1016/S0960-0760(96)00183-5 Pasqualini, 1998, Progestins and Breast Cancer, J. Steroid Biochem. Molec. Biol., 65, 225, 10.1016/S0960-0760(98)00028-4 Rozenbaum H. Les Progestatifs ESKA, Paris; 2002. Sitruk-Ware R, Michelle DR, editors. Progestins and antiprogestins in clinical practice. New York: Marcel Decker; 2000. De Lignierès, 1995, Influence of route of administration on progesterone metabolism, Maturitas, 21, 251, 10.1016/0378-5122(94)00882-8 Rozenbaum H. Comment choisir un progestatif? Reproduction Humaine et Hormones 2000;XIII:3–16. Rozenbaum H. Pharmacology of progesterone and related compounds: dydrogesterone and norpregnane derivatives menopause review 2001;VI:17–28. Neumann, 1998, Entwicklung auf dem Gebiet der Gestagene, Reproduktionsmedizin, 14, 257, 10.1007/s004440050042 Kuhl H. Pharmacology of progestins. Basic Aspects-Progesterone Derivatives. Menopause Review 2001;VI:9–16. Kuhl, 2001, Neue Gestagene-Ihre Vor- und Nachteile, Therapeutische Umschau, 58, 527, 10.1024/0040-5930.58.9.527 Golbs S, Nikolov R, Zimmermann T, Pharmacology of Nortestosterone Derivatives. Menopause Review 2001;VI:31–7. Kumar, 2000, Nesterone: a progestin with a unique pharmacological profile, Steroids, 65, 629, 10.1016/S0039-128X(00)00119-7 Sitruk-Ware, 2002, Progestins in hormonal replacement therapy: new molecules, Risks and Benefits Menopause, 9, 6, 10.1097/00042192-200201000-00003 Rabe, 2000, Induction of estrogen receptor-α and -β activities by synthetic progestins, Gynecol Endocrinology, 14, 118, 10.3109/09513590009167670 Graham, 1997, Physiological action of progesterone in target tissues, Endocrinol. Rev., 52, 502, 10.1210/er.18.4.502